The British Menopause Society Council aims to aid health professionals in providing up to date and informed advice about post reproductive health. This guidance refers to the long-term, but often ignored condition of urogenital atrophy resulting from postmenopausal estrogen deficiency. Treatment should be based on up to date information and targeted to the needs of the individual woman. Non-estrogen- and estrogen-containing treatments are discussed.
SturdeeDWPanayN. on behalf of the International Menopause Society Writing Group Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010. 13. 509–522.
2.
BygdemanMSwahnM. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996. 23. 259–263.
3.
BigliaNPeanoESgandurraP. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010. 26. 404–412.
4.
RosenADRosenT. Study of condom integrity after brief exposure to over-the-counter vaginal preparations. South Med J. 1999. 92. 305–307.
5.
GoldsteinI. Recognising and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt). 2010. 19. 425–432.
6.
SucklingJKennedyRLethabyA. Local estrogen therapy for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006. Issue 4. CD 001500.
7.
WeisbergEAytonEDarlingG. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005. 8. 83–92.
HaspelsAALuisiMKicovicPM. Endocrinological and clinical investigations in postmenopausal women following administration of vaginal cream containing oestriol. Maturitas. 1981. 3. 321–327.
10.
Al-BaghdadiOEwiesAAA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric. 2009. 12. 91–105.
11.
UlrichLNaessenTEliaD. Endometrial safety of ultra-low-dose vagifem 10 µg in postmenopausal women with vaginal atrophy. Climacteric. 2010. 13. 228–237.
12.
NappiREKokot-KierepaM. Vaginal health: insights, views & attitudes (VIVA) – results from an international survey. Climacteric. 2012. 15. 36–44.
13.
CuiYZongHYanH. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 201411. 487–497.
